SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain 10.0% Stake in MoonLake Immunotherapeutics

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reaffirming their beneficial ownership of 10.0% of MoonLake Immunotherapeutics' Class A Common Stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson reported beneficial ownership of 6,306,390.86 shares of MoonLake Immunotherapeutics' Class A Common Stock.
• This represents 10.0% of the total outstanding Class A Common Stock.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported stake.
• The ownership is reported as of December 31, 2024.
• FMR LLC holds sole voting power over 6,305,635.86 shares and sole dispositive power over 6,306,390.86 shares.
• Abigail P. Johnson's beneficial ownership is primarily through her role as Director, Chairman, and CEO of FMR LLC, and her family's controlling interest in FMR LLC.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MoonLake Immunotherapeutics.
• Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing beneficial ownership. It contains factual information about an existing significant stake and does not convey positive or negative sentiment regarding the company's performance or future, beyond the neutral implication of continued institutional investment.

Positives

• Continued significant investment by a major institutional investor (FMR LLC) and its leadership, indicating confidence in MoonLake Immunotherapeutics.
• The holding is stated to be in the ordinary course of business, not for control purposes, suggesting a long-term investment perspective.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, potentially offering a degree of confidence due to the continued holding by a major investor.

Key Dates

Keywords

MoonLake Immunotherapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Management